Bootcamp Gives Residents a Leg Up As part of the Kellogg Eye Center resident training program, Ophthalmology Bootcamp provides residents with opportunities to develop skills in both clinic and operating room settings.
Twice a year, in July and January, the Kellogg Eye Center
holds a two-day course focused on cultivating and developing the clinical and surgical skills of residents in the ophthalmology
Emily Chang, M.D., at the scope during Ophthalmology Bootcamp.
program — before they experience the pressure of taking care of patients and performing surgical procedures on their own.
“Our residents need to develop skills in the clinic and
operating room,” says Shahzad Mian, M.D., vice chair for
including a phacoemulsification wet lab where residents practice
clinical sciences and learning at the Kellogg Eye Center. “Each
cataract surgical skills using synthetic, cadaver, and animal eyes.
resident works one-on-one with doctors on specific skill sets.
Our goal is to make sure they are as well prepared as possible
perform surgical procedures that imitate an actual patient,”
before interacting with patients.”
says Dr. Mian.
In a hands-on clinical setting, residents learn practical skills,
“We also have virtual simulations that enable residents to
Second year ophthalmology resident Tomas Meijome sums
ranging from how to safely gown up before surgery to perform-
up the Ophthalmology Bootcamp as an essential step in his
ing key surgical maneuvers, while also having the opportunity
training. “Having a workshop like this where you’re able to
to ask questions and hone their surgical techniques.
do everything on your own from start to finish is one of those
crucial moments of transitioning from an intern to a resident.”
The course features a medical curriculum with online
components, case presentations and a skills transfer lab,
New Patent for Nanoparticle Therapy in Cancer Howard R. Petty, Ph.D., is professor of
ophthalmology and visual sciences, and of
model, Dr. Petty and his colleagues discovered
microbiology and immunology at Kellogg,
that the new nanoparticle not only killed tumor
where he’s been engaged in research for
cells in the eye, but also extended the survival
nearly 20 years.
of experimental mice bearing 4T1 tumors, a cell
line that is extremely difficult to kill. “Our work
Along with fellow researchers at Kellogg,
Dr. Petty has developed a new nanoparticle
has shown that we can extend the survival of
therapy — Nanoparticle Therapy in Cancer —
mice with this type of tumor.”
that uses a tumor cell's protective mechanism
against itself, essentially short-circuiting tumor
Demirci, M.D., and Cheng-mao Lin, Ph.D., on
cell metabolism and killing tumor cells.
extending this work and ensuring the safety of
the nanoparticle therapy.
This patented technology may help treat
ocular cancer, possibly improving visual and survival outcomes for patients.
12
In a four-year study conducted on a mouse
Dr. Petty is now working with Hakan
